CHICAGO, April 30, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will participate as a panelist at two upcoming conferences.
-
On Monday, May 3, at 2:00 p.m. CDT, Mr. Samant will participate in the panel discussion, "Inside the Boardroom: Industry Opinions on R&D Incentive Proposals," at the Partnering for Global Health Forum (Chicago, May 3 – 4). The panel will be moderated by Hannah Kettler, Ph.D., of the Bill and Melinda Gates Foundation, and includes panelists from Alloy Ventures, Exelixis, Inc., and Vertex Pharmaceuticals. The Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) are sponsoring the Forum, an international partnering conference co-located with the BIO International Convention (Chicago, May 3 – 6). A webcast of the panel discussion will be available through the Events page in the Investors section of the Vical website at www.vical.com.
- On Tuesday, May 4, at 2:00 p.m. CDT, Mr. Samant will participate in the panel discussion, "Vaccines for the 21st Century," at the BIO International Convention, the largest global event for the biotechnology industry featuring hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition. The panel will be moderated by Jeffrey R. Swarz, Ph.D., of Caris & Company, and includes panelists from Merck & Co., Inc., Sanofi Pasteur, Emergent BioSolutions, Inc., and Syntiron.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.